PEG-MGF

PEG-MGF is commonly considered in provider-directed programs focused on the following areas of interest:

• Growth Factor Pathway Support — Often considered in provider-directed programs designed to support growth-factor pathways associated with muscle tissue response and recovery.

• Recovery Support — May be explored within programs focused on recovery following strenuous physical activity, training, or musculoskeletal stress.

• Body Composition Support — May be considered for patients whose goals include body composition and lean-mass-related wellness objectives.

PEG-MGF should be evaluated against applicable prescribing information. Information provided by ALML is intended for healthcare professionals and does not replace independent clinical judgment.

PEG-MGF is a pegylated form of mechano growth factor (MGF), a splice variant of insulin-like growth factor 1 (IGF-1). The pegylation is intended to extend duration of action. Areas of biological activity include:

Areas being studied include:

• MGF / IGF-1 Pathway Activity — PEG-MGF acts within the insulin-like growth factor family, with MGF representing a splice variant that has been studied for distinct biological activity relative to IGF-1.

• Muscle Tissue Response — MGF has been investigated for its association with muscle tissue response following mechanical stress or loading, an area of interest in recovery and regenerative research.

• Pegylation and Extended Duration — The pegylated modification has been studied for its potential to extend the duration of action relative to non-pegylated MGF.

• Recovery and Regenerative Pathways — Preclinical research has explored potential effects on cellular processes associated with tissue repair and recovery.

Clinical use of PEG-MGF varies by patient-specific factors and applicable prescribing information. The treating healthcare professional remains responsible for all clinical decision-making. This information is educational and does not establish clinical efficacy for any specific use.

Healthcare professionals should independently evaluate the available evidence, patient-specific factors, potential risks, and applicable regulatory requirements before considering PEG-MGF for a patient.

Include these considerations:

• Patient-Specific Assessment Required — Providers should consider the patient's medical history, current medications, allergies, pregnancy or breastfeeding status, and other relevant clinical factors before use.

• Use Within Approved and Appropriate Context — PEG-MGF should be evaluated against applicable prescribing information and used only where clinically appropriate for the individual patient.

• Monitor Tolerance and Relevant Clinical Factors — Providers should monitor patient tolerance and relevant clinical factors throughout the course of use.

• Treatment Decisions Remain With the Licensed Healthcare Professional — All treatment, prescribing, and dosing decisions remain solely the responsibility of the appropriately licensed healthcare professional.

ALML provides product and educational information for healthcare professionals. This information is not a substitute for prescribing information, pharmacy labeling, applicable law, or independent clinical judgment.

Verified formulations and strengths will be updated based on current pharmacy availability.